A new cooperative research study including Norris Cotton Cancer Center’s Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC). The multi-institutional study known as the CheckMate 016 study evaluated the...